Offre de thèse
CD Amélioration de la biodisponibilité orale du cannabidiol via l'absorption lymphatique pour action cérébrale : impact de la formulation lipidique
Date limite de candidature
01-06-2025
Date de début de contrat
01-10-2025
Directeur de thèse
LARTAUD Isabelle
Encadrement
4. The scientific leaders; PhD student's host research units 4.1. Human scope This thesis project, co-directed by Pr Isabelle Lartaud and Dr Marianne Parent from CITHEFOR and Pr Socrates Egito from UFRN, will include the participation of other CITHEFOR staff, notably Arnaud Pallotta (assistant professor, analytical chemistry specialist), Thomas Chaigneau (research engineer, analytical chemistry specialist) and Alexandra Kleinclauss (assistant engineer, cell experiments) and UFRN staff with the contribution of the collaborators of Prof. Egito, notably the ones from the Brain Institute of Research, Laboratory of Quality Control and the NUPLAN, a Pharmaceutical Facility of the UFRN in which products in industrial scale are produced for future clinical trials and development of new pharmaceutical products. Drawing on the skills of UFRN and CITHEFOR, with strong local partnerships, the project has a major innovative component in the development of formulations for CBD therapeutic use. Through the Capes-Cofecub program, links have already been forged between the two research units (CITHEFOR and UFRN) for several years now. In particular, Pr Egito has visited France several times, and Dr Parent went to Brazil last winter. Moreover, CITHEFOR is currently welcoming several Brazilian students. A PhD co-supervision is a unique opportunity to pursue and consolidate the collaboration between the two teams. 4.2. Integration and support in the Research Units' strategy CITHEFOR's entire organization is based on a Quality Management System (QMS). This system aims to meet the requirements of ISO 9001 version 2015 and is based on the general principles and recommendations for the Quality approach in research of standard NF X 50-553 of July 2014. The aim is to enable all staff, students and stakeholders to have a complete view of the organization of CITHEFOR team and to integrate seamlessly into it. The Quality Manual, and the documentation derived from it, apply to all the activities of the CITHEFOR team, as well as to all staff, whether permanent or temporary (visiting professors, contract staff, PhD students, trainees, etc.). The Quality Manual is supplemented by procedures and instructions setting out the operational provisions relating to Quality. All newcomers to our organization meet (1) the team manager, who introduces them to our research policy and QMS objectives, and (2) their direct supervisor, who explains how the UR operates. At this stage, training needs for the use of the various equipment (pH meter, automatic pipettes, spectrophotometers and high-performance liquid chromatography, etc.) are assessed and planned. Trainers are designated by the supervisor, based on technical documents and instructions relating to the equipment. (3) The Quality coordinator introduces the newcomer to the team, and gives him or her the Welcome Booklet, which contains the internal regulations and describes the operation of the QMS, outlining the procedures and instructions to be applied. The newcomer certifies that he or she is aware of the health and safety measures in place, and undertakes to comply with the Université de Lorraine's IT Charter and to apply the QMS. The Thesis Charter is then co-signed by the direct supervisor and the doctoral student before the other signatures are obtained. This thesis charter commits the supervisors and the doctoral student to a doctoral program based on defined rules. A visit to the team's premises is organized to enable the newcomer to familiarize himself with his working environment and to meet the research team's staff. In Brazil the applicant will have all the support for produce the new carriers (dosage forms) for CBD, and will be able to deal with a plethora of techniques. The Laboratory of Dispersed Systems (LaSiD), coordinated by Prof. Sócrates Egito, comprises two laboratories, two study and research rooms, and a faculty office, totaling 200 m². Additionally, LaSiD is equipped with various instruments that will support the execution of this proposal, including a Malvern Zetasizer, a Netzsch STA system (TG-DSC), a spectrophotometer, high-precision analytical balances (0.00001 g), an ultrasound probe, a water purification system consisting of a distiller, deionizer, and reverse osmosis system, an ultrasound bath, an Eppendorf centrifuge, Ultra-Turrax agitation systems for different volumes, magnetic stirrers with temperature control, overhead stirrers, rotary evaporators, pH meters for organic and aqueous solutions, a conductometer, a turbidimeter, and other essential equipment. Beyond its in-house infrastructure, LaSiD maintains partnerships with other laboratories at UFRN and collaborating institutions in Brazil (UFRJ, UFMS, and UNESP), which provide the necessary technical support for additional analyses. As a result, the laboratory has unrestricted access to laminar flow hoods for in vitro experiments with human cell cultures, animal facilities, and specialized teams for in vivo studies. Researchers also have access to advanced equipment such as tensiometers, rheometers, ZetaPlus, scanning, transmission, and atomic force electron microscopy, circular dichroism, infrared spectroscopy, GC-FID, and HPLC MS-NMR, among others. Additionally, all researchers have access to auditoriums and amphitheaters, which are suitable for hosting annual scientific discussion meetings. The following paragraphs provide additional information on the support provided. 5. PhD student supervision 5.1. Resources deployed 5.1.1. For the understanding, appropriation and potential development of the project Within UR 3452, various scientific events take place periodically (twice a month), in the form of a presentation of a scientific article related to the subject by one of the team's PhD students, or a presentation of his or her results. This provides an opportunity to confront the literature and receive constructive criticism from UR staff, so as to consolidate the student's progress, either through a bibliographical study, or through additional experimental work. The same activities are offered in LaSiD. Additionally, as part of the formation of the applicant, Masters's student and Young Researchers' students will be guided by the applicant throughout their projects. In this way, the ability to advise students will be developed in the applicant. In addition, the BioSE Doctoral School rules provide for the organization of annual Thesis Follow-up Committees. The supervisors, the doctoral student and two colleagues (one internal to the Université de Lorraine, the other external) take part in these meetings. 5.1.2. for the appropriation of methods and tools CITHEFOR's QMS includes all the team's equipment in a Quality perimeter (arrival on our premises, life sheet, qualification follow-up, etc.) (from the automatic pipette to the most sophisticated equipment, such as dynamic light scattering devices dedicated to nanoparticle size measurement). What's more, the new protocols and methodologies most widely used in the team are drafted by the PhD student, then checked by a second student or a permanent member of staff, and finally validated by another permanent member of staff. Within the LaSiD the applicant will have the opportunity to work with several apparatus after his/her formation by the person responsible of the equipment. He/She will also be able to work with new procedures of a laboratory in which all the equipment has been properly qualified by experts and follow the SOP (Standard Operation Procedures) tailored by each different analysis. 5.1.3. For material, intellectual and personal well-being The PhD student will initially be supported by the research unit's grant, pending the submission of an ANR research project in October 2025 and an Université de Lorraine interdisciplinary project in March 2026. On the LASID side we will try to add funds, if necessary, for a perfect stay in Brazil. The applicant will be placed in a safe environment surrounded by several colleagues who will give all the technical, economical and emotional support to do his/her research work with a great peace of mind. The PhD student will also have easy access to CITHEFOR's computer and bibliographic resources via the team's common server and the Université de Lorraine website, enabling him/her to rapidly acquire a culture of the themes addressed. Doctoral students will be strongly encouraged by their supervisors to join the BioSE Doctoral School's “AD'UL Team” and the ORION scientific clubs (e.g. “What Health”) to facilitate their integration and foster scientific and human exchanges between young researchers. The same environment will be offered at LASID. The research team of Prof. Egito has weekly meeting for discuss science and, after the meeting, we have happy hours for strength the relationship among its members. To support the doctorate and avoid any possible conflict between supervisors and doctoral students, thesis committees will be organized with a time for meetings between invited members and the doctoral student alone. Finally, experiments will be carried out during the day, according to the laboratory's opening hours, with periodic rest periods/holidays. 5.1.4. For the preparation of the defense The BioSE Doctoral School organizes annual meetings of the thesis monitoring committee. The last meeting must authorize the PhD defense, based on the following factors: duration, number of publications and rank of the PhD student in the order of authors, participation in congresses, etc. A written report by colleagues on the thesis monitoring committee is sent to the Doctoral School for this purpose. At the same time, the scientific activities scheduled by UR 3452 and LASID include oral presentations by doctoral students, in particular before their thesis defense, to prepare them for this event by asking questions put forward by the various team members. 5.1.5. Career prospects Through the doctoral training, doctoral student will have consolidated her/his knowledge of pharmaceutical technology, analytical chemistry, in vitro evaluation and pharmacokinetics applied to the development and evaluation of an oral formulation for CBD. Depending on her/his wishes, doctoral student will be guided to help build a curriculum vitae in line with her/his career plans. There are two main ways in which trained doctoral students can enter the professional world: (i) Thanks to the skills acquired, newly-qualified PhD will be able to enter the professional world in a variety of companies, particularly those in the pharmaceutical sector (drugs or medical devices) as young research manager. (ii) The PhD will also have the opportunity to work on contract research contracts (such as post-doctorate or temporary teaching and research assistantship), and subsequently join a company as a senior researcher, or public scientific and technological establishments as a research associate or lecturer. After registering for a PhD, the student must follow the rules of the ED BioSE doctoral school to authorize the defense. A number of these rules are designed to facilitate the professional integration of doctoral students. For example, students must obtain 30 credits before they can defend their doctorate. Some of these credits are earned through participation in scientific conferences, days or congresses, while others are earned through professional integration training courses such as “Ma thèse en 180 secondes”, the Doctoriales de Lorraine or the Doctoriales Européennes, participation in training courses for Doctorants Contractuels Chargés d'Enseignements, or participation in career guidance fairs (training catalogs are available on the doctoral school website). Her/his work will also be submitted for prizes (Faculty of Pharmacy, Université de Lorraine, Académie Nationale de Pharmacie, etc.). The doctoral student may be offered a contract teaching position to gain teaching experience (tutorials and practical work) in disciplines related to his or her research (Pharmaceutical Technology and Biopharmacy). Co-supervision of interns (Master 1, Master 2, introductory research internship, research internship) will be managed by the doctoral student. Doctoral students will be asked to keep their ADUM profile up to date (skills acquired, publications accepted, communications given, etc.) to make them more visible for job offers. In conclusion, all these activities will enable him/her to consolidate his/her profile as a researcher so as to enter the world of work under the most favorable conditions. From our side, at the LaSiD, we are sure that participating in a joint PhD program between France and Brazil offers an exceptional opportunity for the candidate to develop not only advanced technical expertise but also invaluable human and cultural skills. Through this international collaboration, the student will gain access to cutting-edge research facilities, work alongside leading experts, and immerse his/herself in a diverse academic environment that fosters innovation and scientific excellence. Beyond the technical and scientific benefits, this experience will provide a unique opportunity for cultural exchange, allowing the student to engage with peers from different nationalities, perspectives, and research backgrounds. This interaction will enhance his/her adaptability, communication, and problem-solving skills—critical attributes for a successful researcher in today's globalized world. This dual formation will be truly unique, shaping the candidate into a highly skilled researcher or professor capable of training future generations. By fostering knowledge transfer and international collaboration, this initiative will create a positive cycle of scientific advancement, ensuring a lasting impact on academia and innovation.
Type de contrat
école doctorale
équipe
contexte
According to the World Health Organisation's International Clinical Trials Registration Platform, more than 600 clinical trials using cannabidiol (CBD) (including 117 ones actively recruiting) are registered. CBD, one of the main cannabinoids found in cannabis plant is non-psychoactive (unlike tetrahydrocannabinol), but shows many beneficial pharmacological effects in various preclinical models or indications ranging from epilepsy, pain, neurodegenerative diseases such as Alzheimer and Parkinson, inflammatory and autoimmune diseases, cancer, psychiatric and mental diseases (such as anxiety and depression). These pleiotropic effects may be related to modulation of multiple receptors (eg: CB1 and CB2, TRPV, PPAR, GABA-A, 5-HT1A…)1. However, only one CBD monotherapy is currently authorized on the French market: Epidiolex®. It is an oral solution of cannabidiol dissolved in sesame oil and ethanol (with sweetener and flavoring), indicated as adjuvant therapy in certain types of epilepsy. Whether in animal or humans, the beneficial effects of CBD are mostly obtained after oral administration. Yet the oral bioavailability of CBD is really low (between 9 and 13% in humans2) and erratic (intra and inter-individually3). This can be explained by its poor water solubility (log P = 6.97; water solubility 28 mg/L) and its extensive hepatic first-pass metabolism once in the portal circulation. Additionally, CBD is susceptible to oxidation and light degradation4,5. The digestion process is critical for highly lipidic drugs because, depending on their environment, they might be either transferred from intestine cells to portal circulation (where they undergo hepatic metabolism) or to lymphatic circulation (thereby circumventing first-pass metabolism) after integrating chylomicrons6. This is highly dependent of the lipidic environment surrounding the drug in the digestive tract. Indeed, CBD oral bioavailability is 4 times higher when taken with a high fat meal7. Especially, the presence of long chain triglycerides (LCT) is known to stimulate chylomicrons formation8. Thus, the composition of the dietary fat or the lipidic pharmaceutical vehicle will affect lymphatic transport of the drug9. This explain why Epidiolex® is presented in sesame oil containing LCT, although CBD is more soluble in medium-chain triglycerides (MCT). More sophisticated lipidic formulations, such as oil-in-water emulsions, offer additional advantages to drug solubilization. For example, they increase drug bioaccessibility through facilitation of mixed micelles formation during digestion. Modulation of their droplet size might also favorize cellular interaction and uptake10. However, their main limitation is the colloid (un)stability of the emulsion during gastrointestinal digestion under physical and chemical stresses. Pickering emulsions, stabilized by solid particles instead of surfactants, have unique stability against coalescence11. Additionally, the constituents of the particles can play multiple functions, not only as droplets stabilizers but also as protectors against drug oxidation during storage or against degradation into the harsh gastric conditions12. As lipid digestion is a bio-interfacial process, its kinetics is governed by the binding of enzymes, bile salts, and so on, onto the surface of emulsified lipid droplets (either from the formulation “emulsion” or created during food digestion). The project postulates that CBD lipidic solution, surfactant-stabilized emulsion or Pickering emulsion, as they will not offer the same interfacial network, will therefore be digested differently, and finally lead to various oral absorption profiles, rendering the kind of formulation as relevant as its composition. Concerning brain targeting, some fatty acids such as oleic acid have been described to modulate transiently the blood-brain barrier permeability after injection, thus promoting cerebral drug delivery13,14. Theoretically, a similar targeting may be obtained after oral administration, but the literature is still very scarce on this topic15. Nevertheless, a recent article shows that CBD delivery to the brain (in terms of global delivery as well as delivery to the various brain regions) varies depending on the lipidic composition of the oral solution given to the animals16.spécialité
Sciences de la Vie et de la Santé - BioSElaboratoire
CITHEFOR - Cibles thérapeutiques, formulation et expertise pré-clinique du médicament
Mots clés
Cannabidiol, Microémulsion, Emulsion de Pickering, Digestion, Biodistribution
Détail de l'offre
Le cannabidiol (CBD) a un pouvoir anxiolytique et antidépresseur, en plus de propriétés antioxydantes, anti-inflammatoires et neuroprotectrices. Cependant, sa biodisponibilité orale erratique, liée à sa lipophilie et son métabolisme hépatique, entrave son utilisation clinique. Ce projet vise à améliorer la biodisponibilité orale du CBD, en comparaison avec le médicament commercialisé sous forme de solution. Des émulsions (stabilisées par des surfactants ou des particules solides) encapsuleront le CBD et le protégeront de l'oxydation. Leur composition (triglycérides, activateur de perméation, agent stabilisant), leur structure et leur stabilité seront optimisées pour améliorer leur digestion (étude de la lipolyse in vitro) et la délivrance de CBD en favorisant l'absorption lymphatique plutôt que portale (dosage du CBD dans le sang et la lymphe chez la souris après administration orale). La distribution du CBD sera évaluée dans les structures cérébrales (hypothalamus, hippocampe, cervelet, bulbes olfactifs et cortex préfrontal). Une preuve de concept de l'efficacité curative des formulations sera ensuite apportée après administration orale chez des souris exposées à un stress chronique léger et imprévisible, par réversibilité de leur humeur anxiodépressive
Keywords
Cannabidiol, Microemulsion, Pickering emulsion, Digestion, Biodistribution
Subject details
Cannabidiol (CBD) has anxiolytic and antidepressant properties, as well as antioxidant, anti-inflammatory and neuroprotective properties. However, its erratic oral bioavailability, linked to its lipophilicity and hepatic metabolism, hinders its clinical use. This project aims to improve the oral bioavailability of CBD, in comparison with the marketed drug solution. Emulsions (stabilized by surfactants or solid particles) will encapsulate and protect CBD from oxidation. Their composition (triglycerides, permeation enhancer, stabilizing agent), structure and stability will be optimized to improve digestion (study of in vitro lipolysis) and delivery (by favoring lymphatic rather than portal absorption, CBD assay in blood and lymph in mice after oral administration). Distribution of CBD will be assessed in brain structures (hypothalamus, hippocampus, cerebellum, olfactive bulbs and prefrontal cortex). Then, proof of concept of the curative efficacy of the formulations will be provided after oral administration in mice exposed to mild, unpredictable chronic stress, by reversing their anxiodepressive mood.
Profil du candidat
formation dans le domaine des sciences pharmaceutiques
Candidate profile
Training in pharmaceutical sciences
Référence biblio
1. Castillo-Arellano, J., Canseco-Alba, A., Cutler, S. J. & León, F. The Polypharmacological Effects of Cannabidiol. Molecules 28, 3271 (2023).
2. Millar, S. A., Stone, N. L., Yates, A. S. & O'Sullivan, S. E. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 9, 1365 (2018).
3. Schultz, H. B., Hosseini, A., McLachlan, A. J. & Reuter, S. E. Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development. Cannabis and Cannabinoid Research 8, 877–886 (2023).
4. Mazzetti, C., Ferri, E., Pozzi, M. & Labra, M. Quantification of the content of cannabinol in commercially available e-liquids and studies on their thermal and photo-stability. Sci Rep 10, 3697 (2020).
5. Reddy, T. S., Zomer, R. & Mantri, N. Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. Phytotherapy Research 37, 1526–1538 (2023).
6. Porter, C. J. H., Trevaskis, N. L. & Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6, 231–248 (2007).
7. Silmore, L. H., Willmer, A. R., Capparelli, E. V. & Rosania, G. R. Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41, 405–420 (2021).
8. Borel, P. et al. Chylomicron β-Carotene and Retinyl Palmitate Responses Are Dramatically Diminished When Men Ingest β-Carotene with Medium-Chain Rather than Long-Chain Triglycerides12. The Journal of Nutrition 128, 1361–1367 (1998).
9. Feng, W. et al. Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol. Int J Pharm 624, 121947 (2022).
10. Buya, A. B., Beloqui, A., Memvanga, P. B. & Préat, V. Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery. Pharmaceutics 12, 1194 (2020).
11. Tavernier, I., Wijaya, W., Van der Meeren, P., Dewettinck, K. & Patel, A. R. Food-grade particles for emulsion stabilization. Trends in Food Science & Technology 50, 159–174 (2016).
12. Nikbakht Nasrabadi, M., Goli, S. A. H., Sedaghat Doost, A., Dewettinck, K. & Van der Meeren, P. Bioparticles of flaxseed protein and mucilage enhance the physical and oxidative stability of flaxseed oil emulsions as a potential natural alternative for synthetic surfactants. Colloids Surf B Biointerfaces 184, 110489 (2019).
13. Sung, K. S. et al. Saturated Fatty Acid Emulsions Open the Blood-Brain Barrier and Promote Drug Delivery in Rat Brains. Pharmaceutics 16, 246 (2024).
14. Kim, Y.-W. et al. Unsaturated free fatty acid emulsion infusion into carotid artery enhances drug delivery to the rat brain. Brain Behav 13, e2994 (2023).
15. Brookes, A. et al. Is oral lipid-based delivery for drug targeting to the brain feasible? Eur J Pharm Biopharm 172, 112–122 (2022).
16. Brookes, A. et al. Oral lipid-based formulations alter delivery of cannabidiol to different anatomical regions in the brain. Int J Pharm 635, 122651 (2023).
17. Ramos, D. et al. Ibuprofen encapsulation inside non-conventional O/W Pickering emulsions stabilized with partially hydrophobized silica. Front. Coat. Dyes Interface Eng. 2, (2024).
18. Abeyrathne, E. D. N. S., Nam, K. & Ahn, D. U. Analytical Methods for Lipid Oxidation and Antioxidant Capacity in Food Systems. Antioxidants 10, 1587 (2021).
19. Brodkorb, A. et al. INFOGEST static in vitro simulation of gastrointestinal food digestion. Nat Protoc 14, 991–1014 (2019).
20. Zhou, Y. et al. Challenging development of storable particles for oral delivery of a physiological nitric oxide donor. Nitric Oxide-Biol. Chem. 104, 1–10 (2020).
21. Ma, M. et al. LC-MS/MS-based Quantification of Ten Neurotransmitters in Rat Limbic System and Serum: Application to Chronic Unpredictable Mild Stress Induced Depression Rats. Mass Spectrom. Lett. 14, 91–103 (2023).
22. Feng, W. et al. Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. Eur J Pharm Biopharm 162, 43–49 (2021).
23. Zgair, A. et al. Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep 7, 14542 (2017).
24. Ji, L. et al. Rapeseed oleosomes facilitate intestinal lymphatic delivery and oral bioavailability of cannabidiol. Int J Pharm 668, 124947 (2025).
25. Reuveni, N. et al. The antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a preclinical systematic review and meta-analysis. Transl Psychiatry 12, 1–14 (2022).
26. Antoniuk, S., Bijata, M., Ponimaskin, E. & Wlodarczyk, J. Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability. Neuroscience & Biobehavioral Reviews 99, 101–116 (2019).